Imunon Actions

Que fait Imunon ? Imunon Inc is a clinical stage oncology drug company headquartered in Lawrenceville, New Jersey. The company has 31 full-time employees and went public on October 27, 1993. Imunon focuses on developing treatments that leverage the body's natural mechanisms for various diseases. It operates two platform technologies: the TheraPlas platform for immunotherapies and nucleic acid-based anti-cancer therapies, and the PLACCINE platform for nucleic acid vaccines targeting infectious diseases and cancer. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer. IMNN-001 functions by prompting the body to generate cancer-fighting molecules like interleukin-12 and interferon gamma directly at the tumor site. Additionally, Imunon is conducting preclinical research on a nucleic acid vaccine candidate against the SARS-CoV-2 virus to validate its PLACCINE platform. The company's technologies rely on synthetic delivery systems for nucleic acids, avoiding viral vectors or devices. Imunon's website is https://imunon.com/ and it is listed under the ticker IMNN with ISIN US15117N7012. The company operates within the health care sector, specifically in biotechnology. Imunon est l'une des entreprises les plus populaires sur Eulerpool.